Complete response of hepatocellular carcinoma with sorafenib and 90Y radioembolization

Advanced hepatocellular carcinoma has a dismal prognosis, with a median overall survival of 7.9 months if untreated and of 10.7 months if treated with sorafenib. We present a case of advanced previously unresectable hepatocellular carcinoma in a 49-year-old man that achieved a pathologic complete response and was made amenable to surgery with sorafenib in combination with 90Y radioembolization. The patient&rsquo
s survival was more than double the median for patients treated with sorafenib alone.